Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

COVID-19 vaccines remain a cash cow for now

By Brian Buntz | September 21, 2021

Pfizer-BioNTech vaccine

Doses of the COVID-19 vaccine at Walter Reed National Military Medical Center, Bethesda, Md. DoD photo by Lisa Ferdinando.

A handful of companies are making billions of dollars in revenues from COVID-19 vaccines. Especially well-positioned is Pfizer, which could earn $33.5 billion in COVID-19 vaccine sales this year, as it announced in its Q2 earnings statement. By contrast, J&J has forecasted $2.5 billion in COVID-19 vaccine sales this year, while AstraZeneca has seen sales of $1.1 billion in the first half of this year, according to Moody’s.

Analysts are divided, however, on how strong vaccine sales will be in 2022 and beyond.

A report from Moody’s predicts that vaccine sales next year will begin to wane given significant vaccine penetration rates and uncertain demand for boosters. Vaccine penetration rates in many G20 countries have already surpassed 60%. As a result, COVID-19 vaccine revenue in 2022 will “depend to a large extent on how broadly booster shots will be approved and recommended,” wrote Moody’s senior vice president Michael Levesque.

Bloomberg Intelligence senior industry analyst Sam Fazeli concluded that government contracts are likely to guarantee strong vaccine sales in 2022 and possibly 2023.

For instance, Pfizer and BioNTech have agreed to sell up to 1.8 billion doses of their vaccine to the European Union in 2022 and 2023. The agreement includes a firm order of 900 million doses with an option to purchase another 900 million optional ones. If the companies were to sell the entire 1.8 billion doses, the contract would be worth $41.4 billion, with Pfizer and BioNTech splitting the money evenly. Even if the two companies were to only sell 900 million doses, Pfizer and BioNTech would each see $10.35 billion apiece in COVID-19 vaccines sales.

Already, Pfizer’s agreements with the U.K and EU alone are worth as much as $11 billion in 2020.

Bloomberg Intelligence estimates that 2022 sales of the Pfizer-BioNTech vaccine will be worth at least $23.7 billion.

The influx of cash could lead Pfizer to pursue more acquisitions in the near future. Already, the company has agreed to acquire the oncology company Trillium Therapeutics for almost $2.3 billion.

Fazeli, however, concedes that the long-term sales prospects of COVID-19 vaccines are “a lot less certain.”

The prospect of effective mRNA booster doses could lead to a durable immune response. As a result, it “may be possible that further shots of the vaccines may not be needed, or needed only once every three or four years,” Fazeli wrote. But governments may “opt for annual vaccinations if side effects are manageable,” he concluded.


Filed Under: Infectious Disease
Tagged With: AstraZeneca plc, BioNTech, coronavirus, covid-19, COVID-19 vaccine, COVID-19 vaccine trial, COVID-19 vaccines, Janssen, Johnson & Johnson, Pfizer
 

About The Author

Brian Buntz

As the pharma and biotech editor at WTWH Media, Brian has almost two decades of experience in B2B media, with a focus on healthcare and technology. While he has long maintained a keen interest in AI, more recently Brian has made making data analysis a central focus, and is exploring tools ranging from NLP and clustering to predictive analytics.

Throughout his 18-year tenure, Brian has covered an array of life science topics, including clinical trials, medical devices, and drug discovery and development. Prior to WTWH, he held the title of content director at Informa, where he focused on topics such as connected devices, cybersecurity, AI and Industry 4.0. A dedicated decade at UBM saw Brian providing in-depth coverage of the medical device sector. Engage with Brian on LinkedIn or drop him an email at bbuntz@wtwhmedia.com.

Related Articles Read More >

Secretary of Health removes all current members of the CDC advisory committee on immunization practices
covid-19 vaccine
FDA COVID booster pullback jolts vaccine stocks before gains cool
Coronavirus Covid-19 background - 3d rendering
Pregnancy associated with less long COVID: Researchers call for studies on protective biology
How technology advances are helping scientists unlock the mysteries of zoonotic diseases
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE